2022-01-03| Asia-PacificIPO

RNAi Player Sirnaomics Squeezes in $50 Million IPO in Hong Kong

by Joy Lin
Share To

Sirnaomics, a RNA-focused company based in China and the US, raised a little over $50 million in its debut on the Stock Exchange of Hong Kong. The company offered a total of 7.54 million shares at HK$65.90. 

Kunming Jiashiqing and Innoforce Pharmaceuticals have been mentioned as cornerstone investors. 

Despite pricing its shares at the bottom of its predicted range of HK$65.90 to HK$72.70, Sirnaomics’ stock surged 18% on its first day, closing at HK$77.90, putting its market cap at $900 million.  

The public float comes five months after Sirnaomics closed a $105 million Series E round led by Rotating Boulder Fund. And just last year, the company raised the same amount in a Series D round co-led by Rotating Boulder Fund, Walvax Biotechnology and Sunshine Riverhead Capital. 

16 Clinical and Preclinical Assets


According to Sirnaomics, the majority of the proceeds would go into development and commercialization of its small interfering RNA (siRNA) lead pipeline candidate, STP705. Some of the funds will be set aside for other lead candidate STP707 and the GaINAc (N-Acetylgalactosamine) program, which designs liver-targeting siRNAs. The remainder of the proceeds will be used to develop preclinical candidates and support corporate expenses. 

RNA interference, also called RNA silencing, is a cellular gene inhibition mechanism likely evolved to combat foreign agents such as viruses. It typically involves RNA molecules that bind to a target mRNA, which inactivates the mRNA. Thus, the targeted proteins will not be translated and their expression drops. 

Sirnaomics’ STP705 is currently in a Phase 2 study in squamous cell skin cancer. The molecule targets TGF-β1 and COX-2 gene expression. The other lead candidate STP707, which targets the same genes, recently received the FDA go-ahead to begin a Phase 1 trial in solid advanced tumors. 

Besides the two candidates, Sirnaomics is also developing 14 other drugs that cover a variety of cancers, infectious diseases and fibrosis. 

RNA Silencing, a Rarity in China


RNAi is steadily gaining traction in China, with notable deals surfacing in recent months. 

Three weeks ago, Qilu Pharmaceutical struck a licensing agreement worth over $300 million with Arbutus for China rights to Arbutus’ AB-729, a treatment for hepatitis B virus (HBV) infection. 

On the other hand, Hansoh Pharma is turning out to be a major RNAi player in the Chinese market. Since October, the Shanghai-based company has struck three separate licensing deals with Keros, Silence and OliX for their RNAi therapeutics. The combined value of these deals is estimated to be nearly $2 billion.

© All rights reserved. Collaborate with us:
Related Post
Life Began with RNA Theory Gets Renewed Support
China’s Hengrui Buds Off New Biotech With 11 Therapeutic Programs
Kelun Pharmaceuticals to Receive Up To $1.4 Billion From Merck in Lowkey Deal
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
Stanford Touts Remote-Controllable CAR-T Cell Therapy
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
ASCO Annual Meeting
Online and on-side
Digital RESI June
BIO International Convention
San Diego, CA
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!